Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

Abstract Background Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function. Methods We included all participants of the Swiss HIV Cohor...

Full description

Bibliographic Details
Main Authors: Bernard Surial, Matthias Cavassini, Alexandra Calmy, Jan Fehr, Marcel Stöckle, Enos Bernasconi, Bianca Roth, Christoph A. Fux, Helen Kovari, Hansjakob Furrer, Andri Rauch, Gilles Wandeler, the Swiss HIV Cohort Study
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Infectious Diseases
Subjects:
Tenofovir alafenamide
Tenofovir disoproxil fumarate
Antiretroviral therapy
Switch
Toxicity
Online Access:http://link.springer.com/article/10.1186/s12879-019-4454-9

Internet

http://link.springer.com/article/10.1186/s12879-019-4454-9

Similar Items